Free Trial

Veradermics (NYSE:MANE) Major Shareholder Longitude Capital Partners V, Sells 500,000 Shares of Company Stock

Veradermics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Longitude Capital Partners V sold 500,000 Veradermics shares for about $75.2 million at an average price of $150.38, reducing its stake by 21.71% to 1,803,474 shares.
  • Veradermics reported a quarterly loss of $0.50 per share, beating analyst estimates of a $0.59 loss. Shares later traded at $129.18, down $6.11 on the day.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $174.57; ratings include seven Buys, one Hold, and one Sell.
  • MarketBeat previews top five stocks to own in December.

Veradermics, Incorporated (NYSE:MANE - Get Free Report) major shareholder Longitude Capital Partners V, sold 500,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $150.38, for a total value of $75,190,000.00. Following the sale, the insider owned 1,803,474 shares of the company's stock, valued at approximately $271,206,420.12. The trade was a 21.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.

Veradermics Price Performance

Shares of Veradermics stock traded down $6.11 during midday trading on Friday, hitting $129.18. The company had a trading volume of 937,902 shares, compared to its average volume of 651,896. Veradermics, Incorporated has a 1-year low of $32.00 and a 1-year high of $156.63. The business's 50 day simple moving average is $121.56 and its two-hundred day simple moving average is $98.22. The stock has a market cap of $5.45 billion and a PE ratio of -67.99.

Veradermics (NYSE:MANE - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. On average, sell-side analysts expect that Veradermics, Incorporated will post -2.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Veradermics

A number of hedge funds have recently made changes to their positions in the business. Montanova Capital LLC bought a new position in shares of Veradermics during the 2nd quarter worth about $512,533,000. Bamco Inc. NY boosted its position in shares of Veradermics by 284.8% during the 2nd quarter. Bamco Inc. NY now owns 229,581 shares of the company's stock valued at $28,225,000 after acquiring an additional 169,913 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in Veradermics in the second quarter valued at about $9,835,000. Wellington Management Group LLP bought a new stake in Veradermics in the second quarter valued at about $8,425,000. Finally, HighVista Strategies LLC acquired a new position in Veradermics in the third quarter worth about $6,575,000.

Wall Street Analyst Weigh In

MANE has been the subject of several research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Veradermics in a research note on Monday, October 19th. Wall Street Zen upgraded Veradermics from a "sell" rating to a "hold" rating in a research note on Saturday, August 1st. B. Riley Financial upped their price target on Veradermics from $170.00 to $204.00 and gave the company a "buy" rating in a report on Thursday, October 22nd. Weiss Ratings downgraded Veradermics from a "sell (d+)" rating to a "sell (d)" rating in a research report on Wednesday. Finally, Leerink Partners raised their price objective on Veradermics from $135.00 to $150.00 and gave the stock an "outperform" rating in a research report on Monday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Veradermics presently has a consensus rating of "Moderate Buy" and an average price target of $174.57.

View Our Latest Report on Veradermics

About Veradermics

(Get Free Report)

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Veradermics Right Now?

Before you consider Veradermics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradermics wasn't on the list.

While Veradermics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines